The delisting overhang is removed, which is a positive catalyst for a micro-cap stock. However, the company still faces fundamental challenges including a $5M market cap, low revenue base, and ongoing cash needs. Monitor for any subsequent financing or business development announcements that could provide a more durable floor under the stock.
Price Chart
Executive Summary
bioAffinity Technologies (BIAF) announced it has regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) and the Rights/Warrants Rule (5560(a)), following a prior delisting notice triggered by its stock closing below $1.00 for 30 consecutive days. Nasdaq confirmed compliance on September 8, 2026, cancelling the scheduled hearing and allowing BIAF common stock and warrants to continue trading on the Nasdaq Capital Market. This removes the immediate delisting overhang for a micro-cap company with a $5M market cap, but does not change the underlying business fundamentals or revenue trajectory.
Key Facts
- Regained compliance with Nasdaq minimum bid price rule (5550(a)(2)) and Rights/Warrants Rule (5560(a))
- Previously received delisting notice on July 30, 2026 after bid price closed below $1.00 for 30 consecutive business days
- Company was ineligible for the standard 180-day cure period due to a reverse stock split within the prior year
- Nasdaq confirmed compliance on September 8, 2026; scheduled hearing cancelled
- 1,166,625 shares outstanding with aggregate market value of approximately $10.4 million as of September 8, 2026
Financial Impact
Removes delisting risk; aggregate market value of common stock was approximately $10.4 million as of September 8, 2026
Risk Factors
- Company must maintain ongoing compliance with all Nasdaq continued listing requirements
- Low market cap ($5M) and limited float make the stock susceptible to volatility
- No financial results or revenue data in this filing — business fundamentals unchanged
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-041894 |
| Exhibit: ex99-1.htm | 0001493152-26-041894 |
| Document: 0001493152-26-041894-index-headers.html | 0001493152-26-041894 |
| Document: 0001493152-26-041894-index.html | 0001493152-26-041894 |
| Document: 0001493152-26-041894.txt | 0001493152-26-041894 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | DEF 14A | $2.83 | awaiting T+60 | — | $2.96 (+4.59%) |
Oct 15, 2026 12d ago | 8-K | $3.96 | awaiting T+60 | — | $2.96 (−25.25%) |
Oct 13, 2026 14d ago | 8-K | $3.63 | awaiting T+60 | — | $2.96 (−18.34%) |
Oct 9, 2026 18d ago | 8-K | $3.90 | awaiting T+60 | — | $2.96 (+24.10%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (+37.35%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (−37.35%) |
Oct 8, 2026 19d ago | 8-K | $5.64 | awaiting T+60 | — | $2.96 (−47.52%) |
Oct 6, 2026 21d ago | 8-K | $6.06 | awaiting T+60 | — | $2.96 (−51.16%) |
Sep 30, 2026 27d ago | 8-K | $6.56 | awaiting T+60 | — | $2.96 (−54.88%) |
Sep 22, 2026 5w ago | 8-K | $8.56 | awaiting T+60 | — | $2.96 (−65.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers